A5035304428- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Acute Myeloid Leukemia Research
- Economic and Financial Impacts of Cancer
- Acute Lymphoblastic Leukemia research
- CAR-T cell therapy research
- Chronic Myeloid Leukemia Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- CNS Lymphoma Diagnosis and Treatment
- Neutropenia and Cancer Infections
- Hemoglobinopathies and Related Disorders
- Viral-associated cancers and disorders
- Multiple Myeloma Research and Treatments
- Pneumocystis jirovecii pneumonia detection and treatment
- Health Systems, Economic Evaluations, Quality of Life
- Cancer survivorship and care
- Pharmaceutical Economics and Policy
- Epigenetics and DNA Methylation
- Advanced Breast Cancer Therapies
- Cancer Treatment and Pharmacology
- COVID-19 and healthcare impacts
- Monoclonal and Polyclonal Antibodies Research
- Gastrointestinal Tumor Research and Treatment
- Palliative Care and End-of-Life Issues
- Cancer Immunotherapy and Biomarkers
Yale University
2015-2024
Yale Cancer Center
2016-2024
Smilow Cancer Hospital
2018-2024
University of New Haven
2023
Yale New Haven Health System
2021
University of Pennsylvania
2014-2019
Yale New Haven Hospital
2019
Memorial Sloan Kettering Cancer Center
2018
Cornell University
2018
Palmetto Hematology Oncology
2015
Summary A patient with relapsed and refractory chronic lymphocytic leukaemia Richter transformation was treated chimeric antigen receptor ( CAR )‐modified T cells targeted for CD19 but later a clonally related plasmablastic lymphoma. The loss of most routine markers pre‐plasma cell or B lymphoid differentiation (including CD19) highlights the ability such mature lymphomas to evade lineage‐specific immunotherapy by differentiating along pathways comparable their normal cellular counterparts....
Abstract The hypomethylating agents (HMAs) azacitidine and decitabine have been the de facto standard of care for patients with acute myeloid leukemia (AML) who are unfit intensive therapy. Using Surveillance, Epidemiology, End Results-Medicare linked database, we identified 2263 older adults (age ≥66 years) diagnosed AML during 2005-2015 received a first-line HMA; 1154 (51%) azacitidine, 1109 (49%) decitabine. Median survival from diagnosis was 7.1 8.2 months (P < .01) azacitidine-...
Summary Primary mediastinal (thymic) large B‐cell lymphoma ( PMBCL ) is an uncommon subtype of non‐Hodgkin NHL that presents with a mass and has unique clinicopathological features. Historically, patients were treated R‐ CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy ± involved field radiation. Since phase II trial, published in April 2013, demonstrated excellent results using dose‐adjusted DA EPOCH etoposide, prednisone, doxorubicin), this treatment...
Purpose Little is known about the patterns and predictors of use end-of-life health care among patients with acute myeloid leukemia (AML). End-of-life particularly relevant for older adults AML because their poor prognosis. Methods We performed a population-based, retrospective cohort study who were ≥ 66 years age at diagnosis diagnosed during period from 1999 to 2011 died before December 31, 2012. Medicare claims used assess hospice aggressive treatment. Predictors these end points...
Summary The hypomethylating agents ( HMA s) azacitidine and decitabine are both approved for treatment of myelodysplastic syndromes MDS ) in the USA . In Europe, is not due to lack survival advantage randomized trials. two drugs have been compared clinical We identified patients diagnosed with between 2004 2011 from Surveillance, Epidemiology, End Results SEER )‐Medicare linked database who received ≥ 10 doses either estimated initiation Kaplan–Meier methods used multivariate Cox...
Abstract Follicular lymphoma (FL) is traditionally considered treatable but incurable. In March 2021, the US Food and Drug Administration approved use of chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed or refractory (R/R) FL after ≥2 lines therapy. Priced at $373 000, CAR potentially curative, its cost-effectiveness compared other modern R/R treatment strategies unknown. We developed a Markov model to assess third-line vs standard care (SOC) therapies adults FL....
Purpose Surveillance imaging of asymptomatic patients with diffuse large B-cell lymphoma (DLBCL) in first remission remains controversial. A decision-analytic Markov model was developed to evaluate the cost-effectiveness follow-up strategies following first-line immunochemotherapy. Patients and Methods Three were compared 55-year-old patient cohorts: routine clinical without serial imaging, biannual computed tomography (CT) scans for 2 years, or [ 18 F]-fluorodeoxyglucose positron emission...
Abstract Cytarabine-anthracycline based intensive induction chemotherapy (IC) remains the standard of care for remission among fit patients with newly diagnosed acute myeloid leukemia (AML) in United States (US). However, mortality rate outside clinical IC trials, predictors death, and resource utilization during admission have not been thoroughly examined. We used Premier Healthcare database to identify adult (aged 18-89 years) treated cytarabine-anthracycline-based their first recorded...
Abstract Chromosome 1 abnormalities (C1As) are common genetic aberrations among patients with multiple myeloma (MM). We aimed to evaluate the significance of C1As a contemporary cohort MM in United States. used electronic health records from Flatiron Health database select newly diagnosed January 2011 March 2018 who were tested using fluorescence situ hybridization within 90 days diagnosis. characterized as having documented or other high-risk chromosomal (HRCAs) defined by...
PURPOSE The MAIA trial found that addition of daratumumab to lenalidomide and dexamethasone (DRd) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma, compared alone (Rd). However, is a costly treatment administered indefinitely until disease progression. Therefore, it unclear whether cost-effective use the first-line setting reserving its later lines therapy. METHODS We created Markov model compare healthcare costs...
In a recent randomized, open-label trial (ECHELON-1), brentuximab vedotin (BV) combined with doxorubicin, vinblastine, and dacarbazine (AVD+BV) decreased the risk of progression in adults diagnosed stage III or IV Hodgkin lymphoma (HL) compared standard bleomycin-containing chemotherapy (doxorubicin, bleomycin, [ABVD]). However, cost effectiveness incorporating BV (US$6,970 per 50-mg vial) into first-line setting is unknown.
Accurate, patient-centred evaluation of physical function in patients with cancer can provide important information on the functional impacts experienced by both from disease and its treatment. Increasingly, digital health technology is facilitating providing new ways to measure symptoms function. There a need characterise longitudinal measurement characteristics assessments, including clinician-reported outcome, patient-reported ported outcome (PRO), performance tests wearable data, inform...
The first-generation BTK inhibitor ibrutinib is a standard-of-care therapy in the treatment of chronic lymphocytic leukemia (CLL) despite potential side effects that often lead to discontinuation.
Abstract Background Although classical Hodgkin lymphoma (cHL) is highly curable, 20%–30% of patients will not be cured with conventional treatments. The programmed death-1 (PD-1) inhibitors (PD-1i) nivolumab and pembrolizumab have been Food Drug Administration-approved for relapsed/refractory (R/R) cHL. There limited data on the real-world experience PD-1i in cHL it unknown whether fewer selected treated derive benefits similar to those observed published trials. Materials Methods We...